About this trial
This study focuses on rare brain tumors, which are heterogeneous entities with different morphological, biological, and clinical characteristics. Due to their rarity, many of these tumors fall under the RARECARE definition of rare tumors. The main objective of the study is to standardize care models and pathways for patients with rare brain tumors, using Artificial Intelligence (AI) and Machine Learning (ML) techniques to identify specific predictors of postoperative outcomes.
The study includes both retrospective and prospective phases, with the collection of clinical, cognitive, and psychological data at various time points. Patients will undergo an early neuro-cognitive rehabilitation program using the RehaCom software, which will be conducted at home. The goal is to improve the quality of life and care for patients through a multidisciplinary and innovative approach.
Eligibility criteria
Qualifiers
Adults (age ≥18 years)
Both sexes
Patients with rare brain tumors (incidence <6 cases per 100,000 people/year)
Candidates for craniotomy for rare brain tumors
Disqualifiers
Patients undergoing stereotactic/frameless biopsy
Patients with psychiatric disorders or on psychotropic medications
Patients with known cognitive decline (not due to the lesion)
Patients admitted on the same day as the surgery
Trial design
Treatments tested in this trial
- RehaCom
Treatment groups
Sponsors and collaborators
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Lead sponsor
ASL 1 Avezzano Sulmona L'Aquila
Collaborator